DNA Repair
A complete guide to how cells detect and correct DNA damage — covering sources of genomic injury, base excision repair, nucleotide excision repair, mismatch repair, double-strand break repair pathways (HR and NHEJ), direct reversal, translesion synthesis, the DNA damage response, cell cycle checkpoints, hereditary repair disorders, mutational signatures, and the clinical exploitation of repair defects through PARP inhibitors and other targeted therapies.
Every cell in the human body suffers approximately 70,000 DNA lesions every day. Reactive oxygen species generated by normal mitochondrial metabolism oxidise bases; spontaneous hydrolysis removes purines from the sugar-phosphate backbone; replication polymerases occasionally insert the wrong nucleotide; ultraviolet light fuses adjacent pyrimidines; carcinogens covalently attach to bases and distort the helix. Without repair, these lesions would accumulate with every cell division — misread as replication templates, producing mutations that progressively erode the information content of the genome. The human cell has not evolved to avoid DNA damage. It has evolved to fix it — rapidly, accurately, and continuously — through a suite of repair pathways that collectively represent one of the most sophisticated molecular maintenance systems in biology. Understanding DNA repair means understanding not only how genome integrity is preserved across a lifetime of cell divisions but also why it fails — and why that failure, when it occurs in the right genes at the right time, produces cancer.
Sources and Types of DNA Damage — What the Repair System Must Correct
Before examining how DNA is repaired, it is necessary to understand what is being repaired and why. DNA damage is not a rare, exceptional event — it is a constant, universal feature of cellular life that the repair system manages continuously. The molecular variety of DNA lesions is remarkable: from single modified bases to complete disruptions of the double-helix structure, each requiring a structurally and mechanistically different repair response.
Reactive Oxygen Species — The Endogenous Mutagen
Reactive oxygen species (ROS) — superoxide, hydrogen peroxide, and the highly reactive hydroxyl radical — are byproducts of normal oxidative phosphorylation in mitochondria. The hydroxyl radical reacts with DNA bases and the sugar-phosphate backbone, producing over 100 different oxidised DNA lesions. The most biologically significant is 8-oxoguanine (8-oxoG) — an oxidised form of guanine that mispairs with adenine instead of cytosine, causing G→T transversion mutations if not repaired. 8-oxoG is repaired by the BER glycosylase OGG1. A separate system (MutY homologue, MUTYH) removes the adenine that is incorporated opposite 8-oxoG, preventing the mutation from becoming fixed. MUTYH-associated polyposis (MAP) is a hereditary colorectal cancer syndrome caused by biallelic MUTYH mutations.
Depurination and Deamination — Spontaneous Decay
Hydrolytic reactions occur spontaneously in aqueous cellular environments. Depurination — hydrolysis of the N-glycosidic bond between a purine (adenine or guanine) and deoxyribose — produces abasic (AP) sites at a rate of ~10,000/cell/day. AP sites are non-instructional: a replicative polymerase encountering an AP site stalls or inserts adenine by default (the “A-rule”), causing transversion mutations. Deamination — removal of an amino group from a base — most commonly converts cytosine to uracil (~400/cell/day), which pairs with adenine instead of guanine, causing C→T transition mutations. In CpG dinucleotides, methylcytosine deaminates to thymine (not uracil), producing the most common point mutation class in human cancer — C→T at CpG sites.
UV and Ionising Radiation — Environmental Threats
UV-B radiation (280–315 nm wavelengths) from sunlight induces two primary DNA lesions: cyclobutane pyrimidine dimers (CPDs) — covalent bonds between adjacent pyrimidines that distort the helix — and 6-4 photoproducts — a different cross-link between adjacent pyrimidines with even greater helix distortion. Both block replication and transcription and are repaired by nucleotide excision repair. Ionising radiation (gamma rays, X-rays, alpha particles) generates hydroxyl radicals that attack DNA bases and phosphodiester bonds, producing single-strand breaks, base modifications, and — most critically — double-strand breaks. DSBs from ionising radiation are repaired by HR and NHEJ; unrejoined DSBs are lethal, explaining why ionising radiation is effective for cancer treatment.
Alkylating Agents, Crosslinkers, and Intercalators
Chemical mutagens and carcinogens produce diverse DNA lesions. Alkylating agents (methyl methanesulphonate, nitrosamines, cyclophosphamide) add alkyl groups to bases — the most cytotoxic being O⁶-methylguanine (which mispairs with thymine, causing G→A transitions) and 3-methyladenine (which blocks replication). Bifunctional alkylating agents (cisplatin, nitrogen mustards) form intrastrand and interstrand crosslinks that block both replication and transcription. Intercalating agents (acridine dyes, ethidium bromide) insert between base pairs and distort the helix, causing frameshift mutations. Aflatoxin B1 (a mycotoxin) forms bulky guanine adducts causing G→T transversions — the characteristic signature of aflatoxin exposure in hepatocellular carcinoma.
Polymerase Mistakes and Slippage
DNA replication polymerases — despite exquisite proofreading exonuclease activity — occasionally incorporate the wrong nucleotide (~1 error per 10⁷ bases before proofreading; ~1 error per 10⁹ after proofreading). These mismatches are corrected by mismatch repair, reducing the final error rate to ~1 per 10¹⁰ bases. Template slippage during replication of repetitive sequences (microsatellites and minisatellites) generates insertion-deletion loops — extra bases looped out from one strand that are not base-paired with the template — which are also corrected by MMR. Failure of MMR correction at these sites produces the microsatellite instability (MSI) phenotype characteristic of Lynch syndrome and approximately 15% of sporadic colorectal cancers.
Physiological DSBs — Meiosis, V(D)J, and Class Switching
Not all DNA double-strand breaks are accidental damage. Meiotic recombination requires SPO11-generated DSBs in every cell that undergoes meiosis — approximately 200–300 DSBs per meiotic cell, repaired by HR to produce crossovers. V(D)J recombination — the process that generates antibody and T-cell receptor diversity — requires RAG1/RAG2-generated DSBs at immunoglobulin and TCR loci, repaired by NHEJ. Immunoglobulin class-switch recombination (from IgM to IgG, IgA, or IgE) requires AID (activation-induced cytidine deaminase)-generated lesions resolved by NER and NHEJ. These physiological DSBs are precisely controlled and targeted — illustrating that the DSB repair machinery serves essential developmental functions beyond damage response.
How Cells Select a Repair Pathway — Damage Recognition and Pathway Choice
The human cell does not have a single universal repair enzyme — it has multiple specialised repair pathways, each optimised for a different class of DNA damage. The correct pathway must be deployed for each lesion type: using the wrong pathway would be not merely inefficient but actively harmful. The selection of the appropriate repair pathway depends on the structural features of the lesion itself, the cell cycle stage, and which DNA strand (template or newly synthesised) contains the damage.
A Framework for Repair Pathway Organisation
Damage confined to one strand: Single-strand breaks, modified bases, and small distortions use the complementary strand as a template for accurate repair — BER, NER, and MMR all fall into this category. The intact complementary strand provides the sequence information needed for accurate restoration. These pathways are generally high-fidelity because they use undamaged template information.
Both strands damaged at the same site: Double-strand breaks sever both strands of the helix, removing all sequence information at the break site. Two pathways handle DSBs: HR (high-fidelity, requires a sister chromatid template — available in S and G2 phases) and NHEJ (faster, available throughout the cell cycle, but error-prone because no undamaged template is used). The cell cycle stage is therefore a primary determinant of DSB repair pathway choice.
Replication-blocking lesions not repaired before fork arrival: Some lesions escape detection before a replication fork encounters them. Specialised tolerance mechanisms — translesion synthesis and template switching — allow replication to continue past the damage, but accuracy is sacrificed. These are last-resort strategies, not primary repair pathways.
Direct reversal: A small number of lesions can be chemically reversed by specific repair enzymes without excision or resynthesis — the most clinically significant being O⁶-methylguanine repair by MGMT and UV photodimer repair by photolyases (absent in humans). These are the simplest repair mechanisms but apply only to specific lesion types.
Base Excision Repair — Correcting Small Modifications One Base at a Time
Base excision repair is the primary pathway for correcting the most frequent endogenous DNA lesions: oxidised bases, deaminated bases, alkylated bases, and abasic sites. It operates through an elegant four-step logic: a damage-specific glycosylase removes the damaged base; an AP endonuclease cuts the backbone; a DNA polymerase fills the gap; and a DNA ligase seals the nick. The specificity of glycosylases — each recognising a specific structural class of damaged bases — allows BER to target a wide variety of chemically distinct lesions while maintaining high accuracy through the use of the complementary strand as an error-free template.
Step 1 — DNA Glycosylase: Damage Recognition and Base Excision
A damage-specific DNA glycosylase recognises and binds the damaged base, flipping it out of the helix into its active site pocket (base-flipping). The enzyme cleaves the N-glycosidic bond between the damaged base and deoxyribose, releasing the base and leaving an abasic (AP) site in the DNA backbone. Human cells express approximately 11 different DNA glycosylases with overlapping but distinct substrate specificities: OGG1 removes 8-oxoguanine; UNG removes uracil (from cytosine deamination); AAG (MPG) removes 3-methyladenine and hypoxanthine; SMUG1 removes 5-hydroxymethyluracil and uracil; NTH1 and NEIL1/2/3 remove various oxidised pyrimidines. Bifunctional glycosylases (OGG1, NTH1, NEIL1/2/3) additionally cleave the backbone 3′ of the AP site through a lyase activity, combining steps 1 and 2.
Step 2 — AP Endonuclease: Backbone Incision
APE1 (apurinic/apyrimidinic endonuclease 1 — also called HAP1 or APEX1) is the predominant AP endonuclease in human cells and one of the most abundant repair enzymes. It cleaves the phosphodiester backbone immediately 5′ of the AP site, leaving a 3′-OH and a 5′-deoxyribose phosphate (5′-dRP) at the incision. APE1 is a multifunctional protein: its endonuclease domain processes AP sites; it also has 3′-phosphodiesterase activity to remove damaged 3′ termini created by bifunctional glycosylases; and its Ref-1 (redox effector factor 1) domain regulates transcription factor activity — making APE1 a candidate therapeutic target in cancer for its roles in both DNA repair and transcriptional regulation.
Step 3 — DNA Polymerase β: Gap Filling and 5′-dRP Removal
DNA polymerase beta (Polβ) is the principal BER polymerase for short-patch repair. Its 5′-dRP lyase domain removes the 5′-deoxyribose phosphate left by APE1 cleavage; its polymerase domain then inserts a single nucleotide into the one-nucleotide gap using the undamaged complementary strand as template. Polβ is a low-fidelity, distributive polymerase (it lacks proofreading exonuclease activity) — but because it inserts only a single nucleotide guided by an undamaged template, accuracy is effectively enforced by the template sequence rather than polymerase proofreading. Long-patch BER (replacing 2–10 nucleotides) uses pol δ or pol ε with PCNA and FEN1 (to remove the displaced strand flap), generating a longer repair patch — the preferred pathway for certain oxidised AP sites that resist Polβ’s lyase activity.
Step 4 — DNA Ligase: Nick Sealing
DNA ligase IIIα in complex with its scaffold protein XRCC1 seals the remaining single-strand nick in short-patch BER, restoring the intact double helix. XRCC1 is a scaffold protein with no enzymatic activity of its own — it coordinates BER by interacting with Polβ, PARP1, APE1, and DNA ligase IIIα, physically organising the sequential enzymatic steps of short-patch BER into a coordinated complex. PARP1 (poly ADP-ribose polymerase 1) detects single-strand breaks and synthesises poly-ADP-ribose chains to recruit XRCC1 and other BER factors — this PARP1 signalling step is the direct target of PARP inhibitor drugs used in cancer treatment.
Nucleotide Excision Repair — Removing Bulky Helix-Distorting Lesions
Nucleotide excision repair is the most versatile of the DNA repair pathways — it can recognise and remove an enormous variety of chemically unrelated lesions that share a single structural feature: they distort the geometry of the DNA double helix. Rather than using a specific glycosylase for each lesion type, NER uses a damage recognition system that detects helix distortion itself, then excises a short oligonucleotide fragment (~25–30 nucleotides in humans) containing the damage and resynthesises the gap using the complementary strand as template.
Global Genome NER (GG-NER)
GG-NER surveys the entire genome for helix-distorting lesions, regardless of transcriptional activity. The XPC-RAD23B-CETN2 complex is the primary damage sensor — it recognises the distorted DNA structure caused by the lesion rather than the lesion chemistry itself. XPC binding recruits TFIIH, a multisubunit complex containing the XPB and XPD helicases that unwind the DNA around the lesion to expose it. XPA and RPA verify the lesion and stabilise the open complex. The XPF-ERCC1 endonuclease cuts 5′ of the lesion; XPG cuts 3′ of the lesion, releasing the ~25–30 nt damage-containing oligonucleotide. DNA polymerases δ/ε with RFC and PCNA fill the gap; DNA ligase I or the ligase IIIα-XRCC1 complex seals the nick.
Transcription-Coupled NER (TC-NER)
TC-NER specifically repairs lesions in the template strand of actively transcribed genes — giving transcribed genes priority repair access. When RNA polymerase II stalls at a lesion on the template strand, the stalled complex recruits CSB (Cockayne syndrome protein B) and CSA (Cockayne syndrome protein A), which displace the stalled polymerase and recruit the downstream NER machinery. TC-NER is approximately 2–5 times faster than GG-NER for repairing lesions in transcribed genes, explaining why transcribed genes recover faster from UV damage and why mutations are less common in transcribed strand sequences. Defects in TC-NER but not GG-NER cause Cockayne syndrome — characterised by photosensitivity, severe developmental delay, and premature ageing, but not elevated cancer risk.
Xeroderma pigmentosum (XP) is an autosomal recessive disorder caused by mutations in any of eight XP genes (XPA through XPG, plus the variant form XPV caused by pol η mutation). XP patients have severely deficient NER and are exquisitely sensitive to ultraviolet radiation — the sun-exposed skin and eyes accumulate unrepaired UV lesions with every sun exposure. The clinical consequences are severe: a 10,000-fold increased risk of skin cancers (basal cell carcinoma, squamous cell carcinoma, melanoma); a 2,000-fold increased risk of ocular tumours; median age of first skin cancer approximately 8 years; and in approximately 25% of cases, progressive neurological deterioration from neuronal loss.
XP illustrates the direct link between specific DNA repair pathway deficiency and specific cancer types — because the UV photoproducts that NER normally removes are the direct cause of the specific C→T (and CC→TT) mutations at dipyrimidine sites that characterise the UV mutational signature (COSMIC Signature 7). In XP skin, this signature is massively over-represented, particularly in cancer driver genes including TP53 and PTCH1. There is no curative treatment; management is based entirely on UV avoidance, protective clothing, and surveillance for premalignant and malignant skin lesions.
Mismatch Repair — Correcting Replication Errors After the Polymerase
Mismatch repair is the post-replication quality-control pathway that corrects base mismatches and insertion-deletion loops that escape polymerase proofreading during DNA replication. Its contribution to replication fidelity is dramatic — MMR adds approximately 100-fold improvement in accuracy beyond the ~10⁹ error rate achievable by replicative polymerases with proofreading. The combined fidelity of replication plus MMR reduces the per-base error rate to approximately 10⁻¹⁰ to 10⁻¹¹ — one error per cell division across the entire human genome.
MISMATCH RECOGNITION MutSα (MSH2-MSH6) — Recognises base-base mismatches and small IDLs (1–2 nt loops) MutSβ (MSH2-MSH3) — Recognises larger insertion-deletion loops (2–13 nt); partially redundant Both slide along DNA in an ATP-dependent manner after mismatch recognition STRAND DISCRIMINATION AND COORDINATION MutLα (MLH1-PMS2) — Endonuclease; coordinates with MutS and interacts with PCNA/RFC PCNA (loaded at the adjacent replication fork) marks the newly synthesised strand MutLα nicks the newly synthesised strand; this directs excision to the error-containing strand MLH3 — Partners with MLH1 to form MutLγ; role in meiotic mismatch correction PMS1 — Partners with MLH1 to form MutLβ; less well-characterised EXCISION AND RESYNTHESIS EXO1 — 5'→3' exonuclease; excises the error-containing strand from the nick past the mismatch RPA — Stabilises the resulting single-stranded region Pol δ + PCNA + RFC — Resynthesises the excised strand using the template strand as guide DNA Ligase I — Seals the final nick LYNCH SYNDROME GENE-PROTEIN-FUNCTION TABLE MLH1 mutation → ~40% of Lynch syndrome; silenced by methylation in ~15% sporadic CRC MSH2 mutation → ~35% of Lynch syndrome MSH6 mutation → ~10–15%; associated with endometrial cancer predominance PMS2 mutation → ~10%; lower penetrance; associated with Lynch-like syndrome MSI-H phenotype → Predicts response to PD-1/PD-L1 checkpoint immunotherapy across all tumour types
Lynch Syndrome — The Paradigm of Hereditary Mismatch Repair Deficiency
Lynch syndrome (formerly HNPCC — hereditary non-polyposis colorectal cancer) is the most common hereditary colorectal cancer syndrome, caused by germline mutations in MMR genes — most frequently MLH1, MSH2, MSH6, or PMS2. It accounts for approximately 3% of all colorectal cancers and carries lifetime risks of approximately 52–82% for colorectal cancer, 25–60% for endometrial cancer, and elevated risks for ovarian, stomach, urinary tract, and central nervous system cancers. The characteristic molecular feature is microsatellite instability (MSI) — the accumulation of insertions and deletions in short repetitive DNA sequences (microsatellites) throughout the genome, arising from failure to correct slippage errors at these loci. MSI-high (MSI-H) tumours or dMMR (deficient MMR) tumours, detectable by PCR-based MSI testing or immunohistochemistry for MMR proteins, respond dramatically to PD-1 checkpoint inhibitors (pembrolizumab, nivolumab) — a therapeutic connection driven by the hyper-mutated, neoantigen-rich phenotype of MMR-deficient tumours.
Direct Reversal Repair — Chemically Undoing Specific Damage
A small number of DNA lesions can be repaired by direct chemical reversal — the damaged moiety is chemically converted back to the normal base without any excision or resynthesis. This is the simplest possible repair strategy, but it is applicable only to lesions for which a specific reversal enzyme exists. Two direct reversal systems are clinically and biologically significant in humans.
MGMT — O⁶-Methylguanine Reversal
O⁶-methylguanine-DNA methyltransferase (MGMT) directly reverses O⁶-methylguanine — one of the most mutagenic and cytotoxic alkylation lesions — by transferring the methyl group from the O⁶ position of guanine to a cysteine residue in its own active site. This is a suicidal reaction: MGMT is irreversibly inactivated and must be degraded and replaced. Its expression is therefore limiting. MGMT silencing by promoter hypermethylation occurs in ~40% of glioblastomas and sensitises tumours to alkylating chemotherapy (temozolomide) — making MGMT promoter methylation status a predictive biomarker for TMZ response in GBM, assessed routinely in clinical practice.
AlkB Homologues (ALKBH) — Oxidative Dealkylation
The AlkB family of dioxygenases — represented in humans by ALKBH1–8 — directly repair certain N-alkylated base lesions by oxidative dealkylation. The bacterial AlkB enzyme repairs 1-methyladenine and 3-methylcytosine by an oxidative mechanism using oxygen and α-ketoglutarate as co-substrates. Human ALKBH2 and ALKBH3 repair similar lesions in duplex and single-stranded DNA respectively. The ALKBH family also participates in RNA modification and demethylation — including m⁶A demethylation — extending the concept of reversible modification beyond DNA damage to RNA epitranscriptomics.
Photolyases — UV Reversal (Absent in Humans)
Photolyases directly reverse UV-induced cyclobutane pyrimidine dimers and 6-4 photoproducts using energy from visible light (photoreactivation). They are present in bacteria, lower eukaryotes, and many animals, but are absent in placental mammals including humans — explaining why human NER is the sole pathway for UV lesion repair. Cryptochrome proteins (circadian clock regulators in mammals) are structurally related to photolyases but have lost DNA repair activity during evolution. The absence of photolyases in humans means that every UV photodimer must be processed through the multi-step NER pathway, making UV photodimer accumulation particularly problematic in NER-deficient conditions.
Double-Strand Break Repair — The Most Dangerous Lesion and Its Two Solutions
A DNA double-strand break (DSB) severs both strands of the double helix simultaneously — eliminating all base-sequence information at the break site and producing two separate DNA ends that, if left unrepaired, lead to chromosome loss or rearrangement and cell death. DSBs arise from ionising radiation, replication fork collapse at single-strand breaks, certain chemical agents (topoisomerase II poisons, radiomimetic antibiotics like bleomycin), and — physiologically — meiotic recombination, V(D)J recombination, and class switch recombination. They are repaired by two mechanistically distinct pathways with fundamentally different trade-offs between speed and accuracy.
Homologous Recombination
High-fidelity, template-dependent DSB repair using the intact sister chromatid. Available in S and G2 phases only. BRCA1/2-dependent. Error-free when completed correctly — restores exact original sequence.
Non-Homologous End Joining
Rapid, template-independent DSB repair by direct ligation. Available throughout the cell cycle. Ku70/Ku80-dependent. Error-prone — small insertions/deletions at junction common. Predominant pathway in G1.
Alternative End Joining
Backup pathway when canonical NHEJ is unavailable — uses microhomology at DNA ends to align before ligation (also called MMEJ — microhomology-mediated end joining). Highly mutagenic. Strongly associated with chromosomal translocations found in cancer.
Homologous Recombination — High-Fidelity Template-Dependent DSB Repair
Homologous recombination is the pathway that uses an intact copy of the damaged sequence — typically the sister chromatid in S or G2 phase — as a template for accurate repair of DNA double-strand breaks and interstrand crosslinks. It is the only error-free DSB repair pathway for complex lesions where sequence information is lost, and its loss is one of the most common causes of hereditary cancer predisposition — through BRCA1 and BRCA2 mutations — and a major driver of genomic instability in sporadic cancers. HR requires cell cycle phases where a sister chromatid is available; it is therefore suppressed in G1 and maximally active in late S and G2.
DSB Detection — The MRN Complex and ATM Activation
The MRE11-RAD50-NBS1 (MRN) complex is the first responder to DSBs, binding directly to DNA ends within seconds of break formation. MRE11 has nuclease activities; RAD50 has a coiled-coil structure that can bridge two DNA ends; NBS1 (Nibrin) interacts with ATM kinase. MRN binding activates ATM (ataxia-telangiectasia mutated kinase), which autophosphorylates and phosphorylates hundreds of substrates at the break site, including H2AX to form γH2AX — spreading along megabase-scale chromatin domains flanking the break and serving as a platform for repair factor recruitment. γH2AX foci are used experimentally as a sensitive quantitative marker of DSB induction and repair kinetics. NBS1 mutations cause Nijmegen breakage syndrome; MRE11 mutations cause ataxia-telangiectasia-like disorder — both associated with elevated cancer risk and radiation hypersensitivity.
End Resection — Generating 3′ Single-Stranded Overhangs
HR begins with 5’→3′ nucleolytic resection of the DNA ends — degradation of the 5′ strand to generate long 3′ single-stranded overhangs. Resection is a two-step process: MRE11 initiates limited cleavage 5′ of the break; then CtIP (MRN interacting protein) stimulates further resection. Long-range resection is then performed by EXO1 (a 5’→3′ exonuclease) or the DNA2-BLM helicase-nuclease complex, generating kilobase-length single-stranded 3′ tails. This resection step is the critical commitment point for HR: once extensive resection has occurred, the cell is committed to HR rather than NHEJ, because NHEJ requires intact DNA ends. BRCA1 promotes resection; 53BP1 (another γH2AX-binding protein) antagonises resection and promotes NHEJ — the competition between BRCA1 and 53BP1 is a major determinant of pathway choice in G1 versus S/G2 phase.
RAD51 Nucleofilament Formation — The Search for Homology
The 3′ single-stranded overhangs are initially coated by RPA (replication protein A), which stabilises the single-stranded DNA and removes secondary structures. BRCA2 is the central loading factor for RAD51 — it displaces RPA and catalyses the assembly of RAD51 onto the single-stranded DNA to form the RAD51 nucleoprotein filament. This filament — a right-handed helical structure with RAD51 bound cooperatively to ssDNA — is the active molecule for the next step. BRCA1 promotes RAD51 loading indirectly by counteracting 53BP1-mediated inhibition of resection. PALB2 partners with BRCA1 and BRCA2 to coordinate their functions at DSB sites; germline mutations in PALB2 confer an intermediate breast and ovarian cancer risk between heterozygous BRCA1/2 and the general population.
Strand Invasion and D-Loop Formation
The RAD51 nucleofilament performs strand invasion — it searches the genome for a homologous sequence and, upon finding it, invades the intact sister chromatid (or homologous chromosome) and forms a displacement loop (D-loop). The invading 3′ strand is extended by DNA synthesis, using the intact template strand as a guide. The displaced strand of the template (the D-loop strand) can either be re-annealed with the other end of the break (synthesis-dependent strand annealing, SDSA — the predominant mechanism for mitotic HR) or captured to form a double Holliday junction (dHJ) — a structure that can be resolved as either a crossover or a non-crossover. In mitotic cells, non-crossover resolution strongly predominates to avoid chromosomal rearrangements; crossovers are the required outcome in meiosis.
BRCA1 and BRCA2 — The Tumour Suppressors That Guard HR
BRCA1 and BRCA2 are the best-characterised human DNA repair tumour suppressor proteins. BRCA1 (BRCT domain-containing, RING finger ubiquitin ligase) has multiple functions in the DDR — it promotes end resection, coordinates repair factor recruitment via its phosphopeptide-binding BRCT domains, and acts as a transcriptional activator of repair genes. BRCA2 (BRC repeat-containing) is the RAD51 loader — its BRC repeats directly bind RAD51 and deliver it to ssDNA overhangs, enabling nucleofilament formation. Germline mutations in BRCA1 confer ~65–72% lifetime breast cancer risk and ~44% ovarian cancer risk; BRCA2 mutations confer ~45–69% lifetime breast cancer risk and ~17% ovarian cancer risk, plus elevated risks for prostate, pancreatic, and male breast cancers. HR-deficient tumours cannot repair DSBs accurately and are exquisitely sensitive to PARP inhibitors — one of the clearest therapeutic exploitations of a DNA repair defect in oncology.
Non-Homologous End Joining — Rapid but Imprecise DSB Repair
Non-homologous end joining is the predominant DSB repair pathway in human cells — not because it is more accurate than HR (it is not) but because it operates throughout the cell cycle, including in G1 when no sister chromatid is available for HR. NHEJ simply brings the two broken DNA ends together and ligates them, without using any template for sequence information. The result is rapid chromosome re-joining but with frequent loss of nucleotides at the junction — making NHEJ mutagenic. In normal cells, this mutagenicity is acceptable because the alternative (chromosome loss from an unrepaired DSB) is far worse. In cancer cells, accumulated NHEJ-mediated mutations and chromosomal rearrangements contribute to genomic instability and tumour evolution.
The NHEJ Reaction — Ku, DNA-PKcs, and Ligase IV
NHEJ begins when the Ku70-Ku80 heterodimer — one of the most abundant nuclear proteins in human cells — binds to the DNA ends produced at DSBs. Ku is a ring-shaped complex that encircles the double-helix end and slides inward, protecting the ends from excessive nucleolytic degradation while recruiting the downstream NHEJ machinery. Ku binding recruits DNA-PKcs (DNA-dependent protein kinase catalytic subunit) — a large PI3K-like kinase that, when activated by DNA ends, phosphorylates multiple NHEJ factors and autophosphorylates to regulate its own dissociation. DNA-PKcs forms a synaptic complex with the Ku-bound ends of both broken chromosomes, physically bridging the break and holding the ends in proximity.
The ends must often be processed before ligation, because DSB-generated ends rarely have compatible overhangs. The Artemis nuclease — activated by DNA-PKcs phosphorylation — trims 3′ overhangs and hairpin structures. Pol μ and pol λ (low-fidelity polymerases) can fill gaps and extend recessed 3′ ends in a template-dependent or template-independent manner. The final ligation is performed by the XLF-XRCC4-DNA Ligase IV complex, with PAXX and MRI as recently identified accessory factors. The resulting junction often contains short insertions or deletions — the signature of NHEJ. These small indels, if they fall in coding sequences, can disrupt protein function — a mechanism exploited intentionally in CRISPR-Cas9 gene editing to create frameshift mutations that inactivate target genes.
Canonical NHEJ is distinguished from an alternative pathway — alt-EJ (or MMEJ, microhomology-mediated end joining) — which uses short (2–25 bp) microhomologies near the DNA ends as annealing sites before ligation. Alt-EJ is promoted by PARP1 and involves the MRN complex and the POLQ polymerase (also called pol theta). It produces characteristic deletions flanked by the microhomology sequences used for annealing — a mutational signature associated with chromosomal translocations and complex rearrangements in cancer. POLQ (pol theta) is an emerging drug target in HR-deficient tumours: because HR-deficient cells rely more on alt-EJ for DSB repair, POLQ inhibitors are synthetically lethal with BRCA mutations, a potential therapeutic strategy currently in clinical trials.
Translesion Synthesis and DNA Damage Tolerance — Bypassing What Cannot Be Immediately Repaired
DNA damage tolerance mechanisms do not repair lesions — they allow the cell to replicate its genome despite the presence of unrepaired lesions that would otherwise block the replication fork. When a high-fidelity replicative polymerase (pol δ or pol ε) encounters a template lesion, it stalls — because the lesion does not provide the geometric and hydrogen-bonding information the active site requires to select the correct incoming nucleotide. Unresolved replication fork stalls collapse into DSBs, which are more dangerous than the original lesion. Translesion synthesis (TLS) resolves this by recruiting specialised TLS polymerases that can insert nucleotides opposite damaged bases, allowing the replication fork to continue, though often with reduced fidelity.
The decision to recruit TLS polymerases to stalled replication forks is controlled by post-translational modification of PCNA — the sliding clamp that tethers polymerases to DNA and coordinates replication. When a replicative polymerase stalls at a lesion, PCNA is monoubiquitinated at Lys164 by the RAD6-RAD18 ubiquitin ligase complex. Monoubiquitinated PCNA (PCNA-Ub) has higher affinity for Y-family TLS polymerases (through their ubiquitin-binding UBZ or UBM domains), recruiting them to the stalled fork.
Polyubiquitination of PCNA at Lys164 (additional ubiquitin chains added by HLTF and SHPRH ubiquitin ligases) promotes an alternative damage tolerance pathway called template switching (TS), which uses the newly synthesised sister strand rather than a TLS polymerase to bypass the lesion — and is therefore error-free. Template switching is considered a more accurate alternative to TLS but requires RAD51 and is slower. The PCNA ubiquitination state is thus a molecular switch controlling the balance between mutagenic TLS and error-free template switching — a balance that has significant consequences for mutagenesis rates under conditions of genotoxic stress.
The DNA Damage Response — Coordinating Repair with Cell Cycle Arrest and Apoptosis
DNA repair does not operate in isolation — it is embedded within a broader cellular signalling network called the DNA damage response (DDR) that coordinates the detection of damage, cell cycle arrest to provide time for repair, activation of specific repair pathways, and — if repair is unsuccessful — induction of apoptosis or cellular senescence to prevent damaged cells from proliferating. The DDR is a hierarchical signal transduction cascade with sensor kinases at the apex, transducer kinases in the middle, and multiple downstream effectors that each address a specific aspect of the cellular response to damage.
Sensors — ATM and ATR
ATM (PI3K-like kinase) is activated by DSBs via the MRN complex. ATR (another PI3K-like kinase) is activated by RPA-coated single-stranded DNA at stalled replication forks and processed DSB ends — with ATRIP as its obligate binding partner and TopBP1 as the activating cofactor
Transducers — CHK1 and CHK2
CHK1 (downstream of ATR) and CHK2 (downstream of ATM) are serine/threonine kinases that amplify and propagate the damage signal. They phosphorylate CDC25 phosphatases (promoting their degradation) and p53 (stabilising it), enforcing cell cycle arrest at multiple checkpoints
Cell Cycle Arrest — CDC25 and p21
CHK1/CHK2 phosphorylate and target CDC25A (degraded by SCF-βTrCP), CDC25B, and CDC25C (nuclear export via 14-3-3 proteins) for inactivation — preventing CDK activation and arresting the cell cycle at G1/S, intra-S, or G2/M boundaries
Apoptosis and Senescence — p53 Outputs
Stabilised p53 transcribes p21/CDKN1A (cell cycle arrest), PUMA and NOXA (mitochondrial apoptosis), BAX (apoptosis), MDM2 (negative feedback), and GADD45A (repair). The balance between arrest/repair versus apoptosis depends on damage extent, cell type, and p53 post-translational modification
γH2AX — The Molecular Bookmark of DSBs
Phosphorylation of histone H2AX at Serine 139 (producing γH2AX) by ATM and ATR within seconds of DSB formation creates a signal amplification mechanism: γH2AX spreads along megabase chromatin domains flanking the break, creating large γH2AX foci visible by immunofluorescence. These foci serve as scaffolds recruiting MDC1 (which binds γH2AX via its BRCT domains), which recruits RNF8 and RNF168 ubiquitin ligases that modify H2A and H2AX, creating docking sites for 53BP1 and BRCA1. The γH2AX focus persists until DSB repair is complete. Counting γH2AX foci per cell is the most sensitive assay for DSB induction and repair kinetics, used experimentally in radiation biology, DNA repair research, and as a pharmacodynamic biomarker in clinical trials of DDR-targeting agents.
p53 — The Guardian of the Genome
p53 — encoded by TP53, the most commonly mutated gene in human cancer — is the central effector of the DDR decision between repair and apoptosis. Under normal conditions, p53 is rapidly degraded by MDM2-mediated ubiquitination. DNA damage activates ATM/CHK2 and ATR/CHK1 to phosphorylate both p53 (preventing MDM2 binding) and MDM2 (reducing its activity), stabilising p53. Stabilised p53 transcribes either p21 (causing G1 arrest and time for repair) or PUMA/NOXA (triggering intrinsic apoptosis through BAX/BAK pore formation and cytochrome c release). The threshold for p53-mediated apoptosis versus repair depends on damage magnitude, cell type, and p53 modification pattern — explaining why the same DNA damage can cause arrest in one cell type and apoptosis in another.
Hereditary DNA Repair Disorders — When Repair Fails from Birth
Hereditary DNA repair disorders provide the clearest demonstration of the direct connection between specific repair pathway deficiencies and specific disease phenotypes. Each disorder reflects the tissue distribution of cells most vulnerable to the DNA damage type that cannot be repaired, the cell cycle stage most affected, and the types of mutations most likely to accumulate. Together these syndromes represent natural experiments in human DNA repair biology that have shaped our understanding of every major repair pathway.
Relative cancer risk elevation above background in major hereditary DNA repair disorders
Fanconi Anaemia — The Crosslink Repair Syndrome
Fanconi anaemia (FA) is a rare autosomal recessive disorder caused by biallelic mutations in any of 22 FA genes (FANCA through FANCW), all encoding components of the FA pathway for interstrand crosslink (ICL) repair. ICLs covalently link both strands of the helix and are repaired by a complex pathway involving nucleolytic incision around the crosslink (by XPF-ERCC1 and other nucleases), TLS across the unhooked crosslink (by pol η or Rev1-pol ζ), and HR to repair the resulting DSB. The clinical phenotype is severe: bone marrow failure, characteristic radial ray limb defects, other congenital abnormalities, and markedly elevated risks of acute myeloid leukaemia (AML) and solid tumours. FA cells are hypersensitive to crosslinking agents (mitomycin C, cisplatin, diepoxybutane) — this hypersensitivity is used diagnostically. Notably, BRCA1, BRCA2, and PALB2 are FANCD1, FANCD2, and FANCN respectively — directly connecting the FA pathway to the HR pathway and to hereditary breast and ovarian cancer genetics.
Mutational Signatures — Reading Repair History in Cancer Genomes
Every time DNA repair fails to correct a lesion before replication, the lesion is read by a replicative polymerase and results in a mutation. Different types of DNA damage produce characteristic patterns of mutations — mutational signatures — that can be read from the DNA sequence of a cancer genome to reconstruct the repair history of the tumour. The analysis of mutational signatures, pioneered by computational approaches developed at the Wellcome Sanger Institute, has transformed cancer genomics by providing a direct molecular window into the DNA damage and repair processes that shaped each tumour’s genome.
COSMIC Signatures 7a/7b/7c/7d — UV Damage
C→T transitions at dipyrimidine sites (especially TCN → TTN and TCG → TTG) and CC→TT tandem dinucleotide substitutions — the direct consequence of unrepaired UV cyclobutane pyrimidine dimers being bypassed by TLS polymerases. Dominant in cutaneous melanomas and squamous cell carcinomas; massively elevated in XP skin cancers. APOBEC mutagenesis (signatures 2 and 13, C→T and C→G at TCN contexts) arises from APOBEC enzyme activity on ssDNA.
COSMIC Signature 3 — HR Deficiency (HRD)
Broad pattern of deletions at microhomologies and genomic rearrangements, combined with a characteristic substitution profile — associated with BRCA1/2 mutations and other HR-deficient states. The pattern reflects the mutagenic alt-EJ pathway that dominates DSB repair when HR is unavailable. BRCA-ness or genomic scar scores based on signature 3 features are used clinically to identify HR-deficient tumours that may benefit from PARP inhibitors, even in the absence of detectable BRCA1/2 mutations.
COSMIC Signature 6 and MSI Signatures — MMR Deficiency
MMR-deficient tumours accumulate indels at microsatellite sequences throughout the genome, producing the MSI phenotype. Substitution signature 6 (C→T at CpNCpG contexts) is associated with MMR deficiency. MSI-high tumours carry very high total mutation burdens (hundreds of thousands of mutations genome-wide) — the highest of any cancer type — producing abundant neoantigens that make them the tumour type most responsive to PD-1 immune checkpoint inhibition.
Mutational signatures catalogued in COSMIC v3.3 — each representing a distinct DNA damage or repair process operative during cancer evolution
The COSMIC (Catalogue of Somatic Mutations in Cancer) database maintained by the Wellcome Sanger Institute has catalogued over 70 distinct mutational signatures from the analysis of more than 23,000 cancer genomes across 67 cancer types. Each signature represents a combination of six substitution types in their trinucleotide sequence context, providing a 96-channel profile that is computationally decomposed to identify the operative mutational processes. This resource — freely accessible at cancer.sanger.ac.uk — represents one of the most comprehensive accounts of DNA repair process contributions to human cancer ever assembled.
Therapeutic Exploitation of DNA Repair Defects — PARP Inhibitors, Checkpoint Abrogators, and Beyond
The therapeutic exploitation of DNA repair defects is one of the most conceptually elegant areas of cancer pharmacology. The central insight is that many cancer cells have lost one or more DNA repair pathways — either through tumour suppressor gene mutation (BRCA1/2, MMR genes) or through epigenetic silencing (MGMT methylation) — and this loss, while conferring a survival advantage through increased mutagenesis, also creates a specific vulnerability that can be targeted. Normal cells, retaining intact repair, survive the targeted therapy; cancer cells lacking the repair pathway do not. This is the principle of synthetic lethality — the basis of the most successfully targeted DNA repair pharmacology of the past decade.
PARP Inhibitors — Exploiting HR Deficiency
PARP1 detects single-strand breaks and synthesises poly-ADP-ribose (PAR) chains to recruit repair factors. PARP inhibitors trap PARP1 on the DNA as a stable complex (PARP trapping), converting unrepaired single-strand breaks into double-strand breaks at replication forks. In HR-proficient cells, these DSBs are accurately repaired. In BRCA1/2-mutant or otherwise HR-deficient cells, they are irreparable — causing mitotic catastrophe and cell death. Approved PARP inhibitors: olaparib (ovarian, breast, prostate, pancreatic BRCA1/2-mutant cancers), rucaparib, niraparib, talazoparib. The clinical indication has expanded from germline BRCA-mutant tumours to somatic BRCA-mutant and HRD-positive tumours more broadly.
ATR and CHK1 Inhibitors — Abrogating S-Phase Checkpoints
Rapidly dividing cancer cells often have higher levels of replication stress than normal cells — arising from oncogene-driven accelerated replication, insufficient dNTP pools, and high rates of replication fork stalling. ATR (activated by RPA-coated ssDNA at stalled forks) and CHK1 are the primary S-phase checkpoint mediators protecting cancer cells from lethal replication stress. ATR inhibitors (ceralasertib/AZD6738, elimusertib/BAY1895344) and CHK1 inhibitors (prexasertib, adavosertib/WEE1 inhibitor) abrogate this checkpoint, forcing cancer cells into premature mitosis with under-replicated DNA — causing catastrophic chromosomal fragmentation and cell death. These agents are particularly effective in combination with replication-stressing agents (gemcitabine, hydroxyurea) or in cancers with high intrinsic replication stress (KRAS-mutant, MYC-amplified).
DNA-PK Inhibitors — Sensitising to Radiotherapy
DNA-PK (DNA-dependent protein kinase, consisting of the Ku70-Ku80 heterodimer and the DNA-PKcs catalytic subunit) is the master kinase of the NHEJ pathway. DNA-PK inhibitors (M3814/peposertib, AZD7648, CC-122) block NHEJ, preventing repair of DSBs induced by ionising radiation and radiomimetic drugs. In combination with radiotherapy, DNA-PK inhibitors are potent radiosensitisers — an attractive strategy for locally advanced cancers where incomplete repair of radiation-induced DSBs would significantly enhance tumour cell killing without necessarily increasing toxicity to normal tissues (which have intact HR as a backup). Clinical trials combining DNA-PK inhibitors with external beam radiotherapy are ongoing in head and neck, prostate, and pancreatic cancers.
MGMT Methylation and Alkylating Chemotherapy
MGMT promoter methylation — epigenetic silencing of the O⁶-methylguanine repair enzyme — prevents tumours from repairing the O⁶-methylguanine lesions produced by alkylating chemotherapy agents. In glioblastoma (GBM), MGMT promoter methylation (present in ~40% of tumours) is the strongest predictive biomarker for temozolomide (TMZ) response — patients with methylated MGMT have approximately twice the response rate and significantly better survival on TMZ compared to unmethylated tumours. MGMT methylation status is assessed by methylation-specific PCR or pyrosequencing and is now standard clinical practice in GBM treatment planning, guiding the decision between TMZ-based chemoradiotherapy and alternative alkylating agent strategies.
MMR Deficiency and Checkpoint Immunotherapy
MMR-deficient (dMMR) and MSI-high tumours are the most immunotherapy-responsive cancer subtype across all tumour types. The extremely high mutation burden of dMMR tumours generates abundant tumour-specific neoantigens — mutant peptides presented on MHC class I that are not present in normal tissues and are recognised as foreign by T cells. This makes dMMR tumours intrinsically immunogenic but also heavily infiltrated by immunosuppressive regulatory T cells and enriched for PD-L1 expression — explaining their extreme sensitivity to PD-1 checkpoint inhibitors. Pembrolizumab received the first tumour-agnostic FDA approval for any solid cancer in 2017, for dMMR/MSI-H tumours regardless of anatomical origin — a historic milestone linking DNA repair biology directly to precision immunotherapy.
POLQ (Pol Theta) Inhibitors — Targeting Alt-EJ in BRCA-Mutant Tumours
DNA polymerase theta (POLQ), encoded by POLQ, is the key enzyme in the error-prone microhomology-mediated end joining (MMEJ/alt-EJ) pathway. HR-deficient (BRCA1/2-mutant) cells rely heavily on MMEJ for DSB repair — since HR is unavailable. POLQ inhibitors are therefore synthetically lethal with BRCA mutations: BRCA-mutant cells lacking POLQ cannot repair DSBs by either HR or MMEJ, leading to catastrophic genomic instability and cell death, while normal cells retain HR and survive. POLQ inhibitors (RP-3500/camonsertib, ART558, and others) are currently in Phase I/II clinical trials as single agents and in combination with PARP inhibitors, representing the next wave of DNA repair-targeted cancer therapy beyond the established PARP inhibitor class.
DNA Repair in the Academic Context — Study Priorities and Assessment Relevance
DNA repair appears across undergraduate and postgraduate molecular biology, biochemistry, cancer biology, and genetics curricula — and its clinical connections make it increasingly relevant in medical sciences, pharmacy, and nursing pharmacology education. At introductory undergraduate level, students are expected to understand the major repair pathways (BER, NER, MMR, HR, NHEJ), the types of damage each addresses, and the consequences of repair failure. At advanced undergraduate and postgraduate level, content extends to the molecular mechanisms of each pathway, the DDR signalling network (ATM/ATR/CHK1/CHK2/p53), hereditary repair disorders and their clinical features, mutational signatures, and the pharmacological exploitation of repair defects through PARP inhibitors and checkpoint abrogators.
Common examination and assignment topics involving DNA repair include: comparing the mechanisms and fidelity of different DSB repair pathways; explaining why BRCA1/2 mutations predispose to cancer; describing the molecular basis and clinical features of Lynch syndrome or XP; analysing the mechanism of action of PARP inhibitors and the concept of synthetic lethality; explaining how mutational signatures reveal tumour aetiology; and designing experiments to measure DNA repair capacity in cell lines. The primary scientific literature on DNA repair is published in journals including Nature Structural and Molecular Biology, which regularly publishes structural and mechanistic studies on DNA repair complexes that bridge biochemical and structural biology approaches to understanding repair pathway mechanisms.
Students who need support writing essays, research papers, or literature reviews on DNA repair pathways, cancer genetics, or molecular mechanisms of chemotherapy can access specialist academic writing assistance through our biology assignment help, biology research paper service, and science writing services. For longer projects, our literature review service and dissertation support cover the full scope of DNA repair and cancer biology research writing. Complex molecular biology assignments are supported through our complex scientific assignment assistance service.
DNA repair is not a peripheral biological housekeeping function — it is the molecular infrastructure of heredity. Without it, the fidelity of genetic information transmission across cell generations would collapse within a few cell divisions. Every cancer represents, at its most basic level, a failure of this infrastructure at a critical moment.
Principle articulated in seminal reviews including Hoeijmakers (2001, Nature) and Ciccia and Elledge (2010, Molecular Cell)
The discovery that BRCA1/2-mutant tumours are hypersensitive to PARP inhibitors was predicted theoretically from synthetic lethality principles years before it was demonstrated experimentally — one of the rare cases in cancer pharmacology where the drug target and therapeutic mechanism were both specified before the clinical trial began.
Reflecting the work of Lord, Tutt, Bhatt, and colleagues (2006, Nature; Nature Medicine) demonstrating PARP inhibitor synthetic lethality in BRCA-mutant cells
DNA Repair Assignment Support — All Levels and Formats
From undergraduate BER/NER mechanism essays to postgraduate research papers on PARP inhibitor mechanisms and BRCA synthetic lethality — specialist molecular biology writers with subject expertise provide accurate, targeted academic support at every level.
Frequently Asked Questions About DNA Repair
Explore further: biology assignment help · biology research papers · science writing services · research paper writing · literature review writing · dissertation support · chemistry homework help · biostatistics help · data analysis help · complex scientific assignments · challenging research topics · critical analysis papers · nursing assignment help · essay writing services